Omeros Gets Drugs for Bleeding

Xconomy Seattle — 

Omeros (NASDAQ: OMER), the Seattle-based biotech company, said today it has obtained an exclusive license from the University of California to a series of new drug candidates for controlling traumatic bleeding and surgical bleeding. The compounds, which are known as antifibrinolytic agents, are supposed to be safer than Bayer’s aprotinin (Trasylol), which was withdrawn from the U.S. market in 2008. The Omeros drug candidates haven’t yet entered clinical trials.